linjc16/ctgov huggingface dataset:
Effect of Learning on Vegetable Acceptance by Toddlers

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to understand the formation of food preferences from an early age.

Detailed Description
-----------------
The main purpose of this research is to compare the effectiveness of two mechanisms (mere exposure, flavour-flavour learning) in the short and medium term (up to six months after the learning phase) on 2-3 year-old children's vegetable acceptance. the research is conducted on children aged 2 to 3 years in daycares.

Official Title
-----------------
Learning Mechanisms of Food Preferences in 2-3 y. o. Toddlers in Nurseries

Conditions
-----------------
Food Preference

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children between 2 and 3 years, attending daycares returned signed consent form parents Exclusion Criteria: children with food allergies or manifestations, chronic disease or being preterm (<36 weeks gestational age at birth)

Ages Eligible for Study
-----------------
Minimum Age: 17 Months
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Repeated exposure Group (RE)<br>Exposure to basic salsify puree during E1-E8 | |
| Flavour-flavour learning-salt (FFL-S)<br>Exposure to salty salsify puree during E1-E8 | |
| Flavour-flavour learning-nutmeg (FFL-N)<br>Exposure to nutmeg-flavored salsify puree during E1-E8 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vegetable intake and liking | Measure of salsify and carrot puree intake and liking by toddlers at lunch, at pre-exposure before the exposure phase | baseline = Pre-exposure at one week before the beginning of the experimental manipulation (i.e. exposure phase) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vegetable acceptance, vegetable intake, vegetable liking, learning mechanisms, repeated exposure to flavor, flavor learning, replace salt with spice
Effects of the Myofascial Induction Technique Versus a Control Laser

Study Overview
=================
Brief Summary
-----------------
The objective is to determine the effectiveness of myofascial Induction effects on plantar pressures variables. Forty healthy subjects will be recruited for a simple blind clinical trial. All subjects will be randomly distributed in two different groups: control group (sham Laser) and experimental group (myofascial Induction). Outcome measurements will be foot plantar pressure area (footprint) by a validated platform. Two trials will be recorded before and after intervention in standing position.

Official Title
-----------------
Effects of the Myofascial Induction Technique Versus a Control Laser

Conditions
-----------------
Foot Diseases, Myofascial Pain

Intervention / Treatment
-----------------
* Other: Sham Laser
* Other: Myofascial Induction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy individuals without pain. Exclusion Criteria: Previous lower extremities surgery History of lower extremities injury with residual symptoms within the last year Evidence of a leg-length discrepancy of more than 1 cm Evidence of balance deficits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Sham Laser<br>A non-emission laser will be applied in plantar fascia | Other: Sham Laser<br>* Sham Laser in plantar fascia<br>|
| Experimental: Experimental group Myofascial Induction<br>Myofascial Induction in plantar fascia | Other: Myofascial Induction<br>* Myofascial Induction in plantar fascia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plantar pressure measure | Plantar pressure measure by validated footprint platform in grams / square centimeter | Register a plantar pressures of foot print in standing position of 30 seconds | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plantar surface measure | Area of plantar footprint measure by aa validated footprint platform in square centimeters | Register a plantar surface area of foot print in standing position of 30 seconds |
Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

Study Overview
=================
Brief Summary
-----------------
Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very important item required to employees, lost productive time among workers with psychiatric illness should be reduced by the proper management. But few data were reported in this field by now.

Conditions
-----------------
Panic Disorder

Intervention / Treatment
-----------------
* Drug: Paroxetine CR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female outpatients aged 20-50 years In female, is eligible to enter this study if she is if Non-childbearing potential(note:women who are 6 months post-menopausal are not considered women of child-bearing potential) child-bearing potential, has a negative urine dipstick pregnancy test, and is practicing a clinically acceptable method of contraception such as oral contraception, surgical sterilization, I.U.D.,systemic contraception, or double barrier contraception(any two of diaphragm/spermicidal foar/condom) Subject currently meets the diagnosis for PD according to korean version of Anxiety Disorder Interview Schedule for DSM-IV(ADIS-IV) through a comprehensive psychiatric evaluation and not being treated currently. Subject must have the ability to comprehend the key components of the consent form and provide informed consent. Exclusion Criteria: Subject who has a history of any other major medical or psychiatric illnesses except PD or PD with major depressive disorder. Subject who retired or left his job or who plan to retire within two years. is a current homicidal or suicidal risk in the investigator's judgement. is currently pregnant, lactating or planning to become pregnant within the next 3 months is currently participating in any other clinical trial or taking any non-approved or experimental medication.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Paroxetine CR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Panic disorder (PD)
A Static Passive Stretching on Glenohumeral Rotation Range of Movement in Elite Swimmers

Study Overview
=================
Brief Summary
-----------------
Shoulder injury is a common problem of overhead athletes, as swimmers. It's reported a reduction of side-to-side glenohumeral rotation from 11 to 18 degrees can increase 1.9 points the injury risk, because an alteration in biomechanics can turn lead to clinical findings of impingement and labral pathology. Posterior deltoid is a main muscle for propulsion in swimming stroke. To our knowledge, it isn't known how a posterior deltoid static passive stretch could reduce glenohumeral rotation restriction after swimming competition.

Official Title
-----------------
The Effectiveness of a Static Passive Stretching on Glenohumeral Rotation Range of Movement in Elite Swimmers After Competition: A Quasi-experimental Clinical Trial

Conditions
-----------------
Shoulder Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elite swimmers Exclusion Criteria: shoulder surgery dislocation

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of glenohumeral rotation degrees | Internal and external rotation range of movement | Basline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shoulder, glenohumeral, stretching
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)

Study Overview
=================
Brief Summary
-----------------
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule). The study focusses on concomitant antiemetic therapy and patient compliance.

Official Title
-----------------
Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer

Conditions
-----------------
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years old Male and female patients Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC Therapy with Navelbine capsules in any palliative treatment line Signed patient informed consent Exclusion Criteria: Pregnancy and nursing All other exclusion criteria listed in SPC (summary of product characteristics) lack of signed Patient informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NSCLC<br>Patients with advanced non-small cell lung cancer | |
| MBC<br>Female patients with metastatic, Anthracycline-resistent breast cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free-survival |  | 1 year after LPI | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to progression |  | 1 year after LPI | 
| Adverse reactions |  | 1 year after LPI | 
| Concomitant antiemetic therapy |  | 1 year after LPI | 
| Patient compliance |  | 1 year after LPI | 
| Recording of combinations of applied capsules (requested by a patients' questionnaire) |  | 1 year after LPI | 
| General condition of patients (requested by a patients' questionnaire) |  | 1 year after LPI | 
| Therapy performance in the daily routine |  | 1 year after LPI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MBC, germany, NSCLC, non small cell lung carcinoma, metastatic breast cancer, advanced breast cancer, Navelbine, Navelbine-ORAL, Vinorelbine, Vinorelbine-ORAL, daily routine, concomitant antiemetic therapy, patient compliance, non-interventional study, oral anti cancer therapy, quality of life
Personalized Medicine in Patients With Infective Endocarditis

Study Overview
=================
Brief Summary
-----------------
The hypothesis underlying this work is the identification of different sub phenotypes of patients with infective endocarditis through the study of the host's response to infection. Furthemore, metagenomic sequencing may be a helpful supplement to IE diagnostic, especially when conventional tests fail to yield a diagnosis.

Detailed Description
-----------------
Infective endocarditis is a life-threatening infection of heart valves and adjacent structures characterized by vegetations on valves and other endocardial surfaces, with tissue destruction and risk of embolization. The clinical variability, including the heterogeneous response to infection and the different antibiotic treatments make the identification of the underlying pathogens of infective endocarditis (IE) is critical for precision therapy. Virulence factors mediate tissue adherence, host infiltration, immune resistance/evasion, and dynamic stress responses and confer enhanced pathogen survival, proliferation, and host invasion in animal models of infective endocarditis. To identify the microorganism and simultaneously considered the response of the host to the infection could improve the management of the infective endocarditis.

Official Title
-----------------
Personalized Medicine in Patients With Infective Endocarditis

Conditions
-----------------
Infective Endocarditis, Response, Acute Phase, Treatment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of active infective endocarditis according to the modified Duke criteria. Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize a cohort of patients diagnosed with infective endocarditis | Clinical, microbiological and echocardiographic description of patients with infective endocarditis. | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of the underlying pathogens of infective endocarditis (IE) | We will employ next-generation sequencing for pathogens and antimicrobial resistance detection in IE patients. | 2 year | 
| Host response classification for infective endocarditis (IE) | Differential baseline expression of some genes may indicate resilience to infection. | 2 year | 
| Host response predictors of sepsis outcomes | We will develop and use advanced bioinformatic, metabolomic, proteomic and mRNA sequencing technologies to identify specific changes, or biomarkers, in patient blood samples that predict outcome in sepsis. | 2 year |
Prognostic Biomarkers in Patients With Urothelial Carcinoma

Study Overview
=================
Brief Summary
-----------------
Bladder cancer (BC) is a heterogeneous malignancy with dismal outcome.Despite treatment, the 5-year overall survival rates for MIBC are <50%, with many patients unresponsive or inapt, necessitating biomarkers to select those most likely to respond or fit for treatment

Detailed Description
-----------------
In this study was assessed the associations among most frequently mutated genes and with clinicopathological features, as well as the prognostic significance of the presence of mutations in the top mutated and DNA Damage response (DDR) mutated genes in terms of Overall Survival (OS). Moreover, overall tumor-infiltrating lymphocytes (TILs) density was measured, analyzed immunohistochemically the expression of PD-L1, the four MMR proteins (MLH1, MSH2, MSH6 and PMS2) and tumor or stromal CD8+ cytotoxic T lymphocyte infiltrates and assessed their association with each other, top mutated genes and available clinicopathological parameters together with their role in prognosis.

Official Title
-----------------
Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens

Conditions
-----------------
Bladder Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Urothelial carcinoma located in bladder Patients treated with platinum regimens at the neoadjuvant . adjuvant setting Written informed consent for the use of biological material Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of mutational profile in patients with urothelial carcinoma |  | Up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of mutational profile with PD-L1 expression |  | Up to 5 years | 
| Association of the prognostic significance of mutations with respect to overall survival |  | Up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CD8, Next Generation sequencing, TP53, ARID1A, ERCC2, BRACA2, DNA damage response, platinum sensitivity, muscle invasive, PD-L1, TILs, MMR
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Study Overview
=================
Brief Summary
-----------------
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

Official Title
-----------------
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: Reminyl retard


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA Underwritten study consent No treatment with acetylcholinesterase inhibitors Mini-Mental-State Examination: 12-25 points Age: 50-80 Years Orale contraception for women of child-bearing age Exclusion Criteria: Mental Disorders Other Diseases of the CNS Severe Illness Contraindication for MRI-Scan Contraindication for Galantamin (Reminyl retard®) Participation at other clinical trials

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CASL-MRI<br>Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl | Drug: Reminyl retard<br>* retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral perfusion |  | baseline and after 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog) |  | baseline, after 12 and 24 weeks | 
| Alzheimer's Disease Functional Assessment and Change Scale (ADFACS) |  | baseline, after 12 and 24 weeks | 
| Neuropsychiatric Inventory (NPI) |  | baseline, after 12 and 24 weeks | 
| Mini-Mental-Status-Examination (MMSE) |  | baseline, after 12 and 24 weeks |
Posterior Cornea in Primary Open Angle Glaucoma

Study Overview
=================
Brief Summary
-----------------
Characterization of posterior corneal changes in primary open angle glaucoma patients, using Scheimpflug examination.

Detailed Description
-----------------
A cohort of primary open angle glaucoma (POAG) patients is submitted to Scheimpflug Pentacam examination. The results are compared with a control group of age and central corneal thickness matched healthy subjects

Official Title
-----------------
Posterior Cornea in Primary Open Angle Glaucoma

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Procedure: Pentacam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary open angle glaucoma, with the diagnosis supported on structural and functional complementary exams according to the current European Glaucoma Society guidelines Healthy subjects from the General Ophthalmology Outpatient Clinic Exclusion Criteria: age inferior to 18 years old primary closed angle glaucoma secondary open angle glaucoma previous intra-ocular surgery known or suspected corneal disease previous intra-ocular inflammation previous ocular trauma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases<br>Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination | Procedure: Pentacam<br>* Corneal topography using Scheimpflug Pentacam examination<br>|
| Controls<br>Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination | Procedure: Pentacam<br>* Corneal topography using Scheimpflug Pentacam examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean posterior corneal elevation | Mean posterior corneal elevation based on the relative elevation of the cornea related with the best-fit sphere | Single point in time, at baseline at the moment of study enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean anterior corneal elevation | Mean anterior corneal elevation based on the relative elevation of the cornea related with the best-fit sphere | Single point in time, at baseline at the moment of study enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cornea, glaucoma, primary open angle glaucoma